JLE

Epileptic Disorders

MENU

Unverricht-Lundborg disease Volume 18, supplément 2, September 2016

  • [Arundine et al., 2003] Arundine M., Chopra G.K., Wrong A. Enhanced vulnerability to NMDA toxicity in sublethal traumatic neuronal injury . J Neurotrauma. 2003;20:1377-1395. in vitro
  • [Ben-Menachem et al., 2000] Ben-Menachem E., Kyllerman M., Marklund S. Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res. 2000;40:33-39.
  • [Berkovic et al., 1986] Berkovic S., Andermann F., Carpenter S., Andermann E., Wolfe L.S. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med. 1986;315:296-305.
  • [Buzzi et al., 2012] Buzzi A., Chikhladze M., Falcicchia C. Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiol Dis. 2012;47:216-224.
  • [Chew et al., 2008] Chew N.K., Mir P., Edwards M.J. The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord. 2008;23:107-113.
  • [Chong et al., 2005] Chong Z., Li F., Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005;75:207-246.
  • [Cooper, 2010] Cooper J.D. The neuronal ceroid lipofuscinoses: the same, but different? Biochem Soc Trans. 2010;38:1448-1452.
  • [de Haan et al., 2004] de Haan G.J., Halley D.J., Doelman J.C. Unverricht-Lundborg disease: underdiagnosed in the Netherlands. Epilepsia. 2004;45:1061-1063.
  • [Edwards et al., 2002] Edwards M.J., Hargreaves I.P., Heales S.J. N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects. Neurology. 2002;59:1447-1449.
  • [Eldridge et al., 1983] Eldridge R., Iivanainen M., Stern R., Koerber T., Wilder B.J. “Baltic” myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet. 1983;2:838-842.
  • [Ferlazzo et al., 2007] Ferlazzo E., Magaudda A., Striano P. Long-term evolution of EEG in Unverricht-Lundborg disease. Epilepsy Res. 2007;73:219-227.
  • [Ferlazzo et al., 2009] Ferlazzo E., Gagliano A., Calarese T. Neuropsychological findings in patients with Unverricht-Lundborg disease. Epilepsy Behav. 2009;14:545-549.
  • [Ferlazzo et al., 2009] Ferlazzo E., Italiano D., An I. Description of a family with a novel progressive myoclonus epilepsy and cognitive impairment. Mov Disord. 2009;24:1016-1022.
  • [Franceschetti et al., 2007] Franceschetti S., Sancini G., Buzzi A. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiol Dis. 2007;25:675-685.
  • [Franceschetti et al., 2014] Franceschetti S., Michelucci R., Canafoglia L. Progressive myoclonic epilepsies: definitive and still undetermined causes. Neurology. 2014;82:405-411.
  • [Genton and Guerrini, 1990] Genton P., Guerrini R. Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology. 1990;40:1412-1416.
  • [Genton et al., 2006] Genton P., Gélisse P., Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia. 2006;47:2083-2085.
  • [Genton et al., 2012] Genton P., Delgado Escueta A., Serratosa J.M., Michelucci R., Bureau M. Progressive myoclonus epilepies. In: Bureau M., Genton P., Delgado Escueta A., Dravet Ch., Tassinari C.A., Thomas P., Wolf P., eds. Epileptic Syndromes in Infancy, Childhood and Adolescence (5th ed). John Libbey Eurotext Ltd; 2012575-606.
  • [Giovagnoli et al., 2009] Giovagnoli A.R., Canafoglia L., Reati F. The neuropsychological pattern of Unverricht-Lundborg disease. Epilepsy Res. 2009;84:217-223.
  • [Houseweart et al., 2003] Houseweart M.K., Pennacchio L.A., Vilaythong A., Peters C., Noebels J.L., Myers R.M. Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J Neurobiol. 2003;56:315-327.
  • [Hurd et al., 1996] Hurd R.W., Wilder B.J., Helveston W.R., Uthman B.M. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with nacetylcysteine. Neurology. 1996;47:1264-1268.
  • [Joensuu et al., 2008] Joensuu T., Lehesjoki A.E., Kopra O. Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia. 2008;49:557-563.
  • [Joensuu et al., 2014] Joensuu T., Tegelberg S., Reinmaa E. Gene expression alterations in the cerebellum and granule neurons of Cstb(-/-) mouse are associated with early synaptic changes and inflammation. PLoS One. 2014;9:e89321.
  • [Kälviäinen et al., 2008] Kälviäinen R., Khyuppenen J., Koskenkorva P., Eriksson K., Vanninen R., Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia. 2008;49:549-556.
  • [Khiari et al., 2009] Khiari H.M., Franceschetti S., Jovic N., Mrabet A., Genton P. Death in Unverricht-Lundborg disease. Neurol Sci. 2009;30:315-318.
  • [Koskenkorva et al., 2009] Koskenkorva P., Khyuppenen J., Niskanen E. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology. 2009;73:606-611.
  • [Koskiniemi et al., 1974] Koskiniemi M., Toivakka E., Donner M. Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand. 1974;50:333-359.
  • [Kunz, 2002] Kunz W.S. The role of mitochondria in epileptogenesis. Curr Opin Neurol. 2002;15:179-184.
  • [Kyllerman et al., 1991] Kyllerman M., Sommerfelt K., Hedström A., Wennergren G., Holmgren D. Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia. 1991;32:900-909.
  • [Lafreniere et al., 1997] Lafreniere R.G., Rochefort D.L., Chretien N. Unstable insertion in the 5’ flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat Genet. 1997;15:298-302.
  • [Lalioti et al., 1997] Lalioti M.D., Scott H.S., Buresi C. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 1997;386:847-851.
  • [Lehtinen et al., 2006] Lehtinen M.K., Yuan Z., Boag P.R. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell. 2006;125:987-1001.
  • [Lehtinen et al., 2009] Lehtinen M.K., Tegelberg S., Schipper H. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci. 2009;29:5910-5915.
  • [Lundborg, 1903] Lundborg H. Die progressive Myoclonusepilepsie (Unverricht's Myoklonie). Uppsala: Almqvist and Wiskell; 1903.
  • [Magaudda et al., 2006] Magaudda A., Ferlazzo E., Nguyen V.H., Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia. 2006;47:860-866.
  • [Manninen et al., 2014] Manninen O., Laitinen T., Lehtimäki K.K. Progressive volume loss and white matter degeneration in Cstb-deficient mice: a diffusion tensor and longitudinal volumetry MRI study. PLoS One. 2014;9:e90709.
  • [Manninen et al., 2015] Manninen O., Koskenkorva P., Lehtimäki K.K. White matter degeneration with Unverricht-Lundborg progressive myoclonus epilepsy: a translational diffusion-tensor imaging study in patients and cystatin B-deficient mice. Radiology. 2015;269:232-239.
  • [Marseille Consensus and Group, 1990] Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Marseille Consensus Group. Ann Neurol. 1990;28:113-116.
  • [Minassian et al., 2016] Minassian B.A., Striano P., Avanzini G. Progressive Myoclonus Epilepsies: State-of-the-Art. Epileptic Disord. 2016;18:S1-S158. Suppl. 2
  • [Muona et al., 2015] Muona M., Berkovic S.F., Dibbens L.M. A recurrent mutation in KCNC1 causes progressive myoclonus epilepsy. Nat Genet. 2015;47:39-46. de novo
  • [Mumoli et al., 2015] Mumoli L., Tarantino P., Michelucci R. No evidence of a role for cystatin B gene in juvenile myoclonic epilepsy. Epilepsia. 2015;56:e40-43.
  • [Okuneva et al., 2015] Okuneva O., Körber I., Li Z. Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1. Glia. 2015;63:400-411.
  • [Pennacchio et al., 1996] Pennacchio L.A., Lehesjoki A.E., Stone N.E. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science. 1996;271:1731-1734.
  • [Pennacchio et al., 1998] Pennacchio L.A., Bouley D.M., Higgins K.M., Scott M.P., Noebels J.L., Myers R.M. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet. 1998;20:251-258.
  • [Pranzatelli et al., 1995] Pranzatelli M.R., Tate E., Huang Y. Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-Ltryptophan. Epilepsia. 1995;36:783-791.
  • [Rinne et al., 2002] Rinne R., Saukko P., Jarvinen M., Lehesjoki A.E. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. Ann Med. 2002;34:380-385.
  • [Schmued and Hopkins, 2000] Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000;874:123-130.
  • [Selwa, 1999] Selwa L.M. N-acetylcysteine therapy for Unverricht-Lundborg disease. Neurology. 1999;52:426-427.
  • [Shannon et al., 2002] Shannon P., Pennacchio L.A., Houseweart M.K., Minassian B.A., Myers R.M. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J Neuropathol Exp Neurol. 2002;61:1085-1091.
  • [Smith et al., 2000] Smith B., Shatz R., Elisevich K., Bespalova I.N., Burmeister M. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia. 2000;41:1046-1048.
  • [Tegelberg et al., 2012] Tegelberg S., Kopra O., Joensuu T., Cooper J.D., Lehesjoki A.E. Early microglial activation precedes neuronal loss in the brain of the Cstb-/- mouse model of progressive myoclonus epilepsy, EPM1. J Neuropathol Exp Neurol. 2012;71:40-53.
  • [Unverricht, 1891] Unverricht H. Die Myoclonie. Leipzig, Wien: Franz Deuticke; 1891.
  • [Vaarmann et al., 2006] Vaarmann A., Kaasik A., Zharkovsky A. Altered tryptophan metabolism in the brain of cystatin B-deficient mice: a model system for progressive myoclonus epilepsy. Epilepsia. 2006;47:1650-1654.
  • [Vanni et al., 2014] Vanni N., Fruscione F., Ferlazzo E. Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Ann Neurol. 2014;76:206-212.
  • [Wille et al., 2011] Wille C., Steinhoff B.J., Altenmüller D.M. Chronic high-frequency deep-brain stimulation in progressive myoclonic epilepsy in adulthood-report of five cases. Epilepsia. 2011;52:489-496.